Syndax Adds Two Pipeline Assets and Lays Out a Catalyst-Rich Roadmap
SNDX has more than doubled off its 52-week low of $9.03.
Summary
Syndax announced two new pipeline assets—SNDX-4321 for EGFR-mutant NSCLC and SNDX-62122 for myelofibrosis—and confirmed multiple near-term catalysts, including Phase 2 data for axatilimab in IPF in Q4 2026.
Key Events · Product Development and Regulatory · SNDX
-
New Pipeline Asset SNDX-4321 Unveiled
A novel, mutant-selective, allosteric EGFR inhibitor for NSCLC, SNDX-4321 targets L858R mutations, CNS metastases, and atypical mutations. An IND submission is expected by YE 2026, with Phase 1 initiation in 2027.
-
Next-Gen Menin Inhibitor SNDX-62122 Selected for MF
The first candidate from an internally developed library of next-gen menin inhibitors, SNDX-62122, will be developed for myelofibrosis. An IND submission is expected in 2027, with development informed by a revumenib proof-of-principle trial starting in Q4 2026.
-
Multiple Near-Term Catalysts Confirmed
Topline data from the Phase 2 MAXPIRe trial of axatilimab in IPF are on track for Q4 2026. A Phase 1/2 proof-of-principle trial of revumenib in MF is set to initiate in Q4 2026, with initial data in 2H27. Multiple revumenib readouts in acute leukemia are expected in 2H26+.
-
Pipeline Expansion Beyond Approved Drugs
The new assets broaden the pipeline beyond Revuforj and Niktimvo, targeting blockbuster opportunities in NSCLC and MF. Four innovative assets are expected in the clinic by 2027.
Analysis · SNDX · Life Sciences
The pipeline is expanding with two new assets that open fresh growth avenues beyond Revuforj and Niktimvo: SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. Meanwhile, the Phase 2 trial of axatilimab in IPF remains on track for topline data in Q4 2026, and a proof-of-principle trial of revumenib in MF will begin in Q4 2026. With multiple readouts expected in the second half of 2026 and four assets potentially in the clinic by 2027, this R&D update materially de-risks the pipeline and sets up a catalyst-rich period that could drive significant value.
At the time of this filing, SNDX was trading at $22.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $9.03 to $25.59. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.